Anemia management in the era of triple combination therapy for chronic HCV

Ira M. Jacobson, Kris V. Kowdley, Paul Y. Kwo

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Boceprevir or telaprevir plus ribavirin (RBV) and pegylated interferon-α (pegIFN-α) is the new standard-of-care therapy for patients who are chronically infected with genotype 1 hepatitis C virus (HCV). The addition of these protease inhibitors to the RBV/pegIFN-α combination regimen has significantly improved rates of sustained virologic response (SVR); however, the incidence of anemia has also increased significantly. Anemia can interfere with patients' quality of life, work productivity, and treatment adherence. Severe anemia can cause morbidity and even mortality. For the management of anemia during triple combination therapy, RBV dose reduction is recommended as an initial course of action. Retrospective analyses of carefully selected patient cohorts suggest that RBV dose reduction does not reduce SVR rates. However, this observation needs to be confirmed in prospective trials with cohorts that more accurately reflect the challenging patients treated in real-world practice. Adequate doses of RBV should be maintained during triple combination therapy, as phase II trials have demonstrated that RBV is essential for attaining optimal SVR rates and preventing viral breakthrough, relapse, and emergence of resistant variants. This roundtable addresses key points related to the management of anemia in the era of triple combination therapy, including the increasing problem of anemia, strategies for anemia management, and the importance of maintaining adequate RBV exposure as part of the HCV treatment regimen.

Original languageEnglish
Pages (from-to)3-15
Number of pages13
JournalGastroenterology and Hepatology
Volume8
Issue number9
StatePublished - Sep 2012

Fingerprint

Ribavirin
Chronic Hepatitis C
Hepacivirus
Anemia
Interferons
Therapeutics
Standard of Care
Protease Inhibitors
Genotype
Quality of Life
Morbidity
Recurrence
Mortality
Incidence
Sustained Virologic Response

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Jacobson, I. M., Kowdley, K. V., & Kwo, P. Y. (2012). Anemia management in the era of triple combination therapy for chronic HCV. Gastroenterology and Hepatology, 8(9), 3-15.

Anemia management in the era of triple combination therapy for chronic HCV. / Jacobson, Ira M.; Kowdley, Kris V.; Kwo, Paul Y.

In: Gastroenterology and Hepatology, Vol. 8, No. 9, 09.2012, p. 3-15.

Research output: Contribution to journalArticle

Jacobson, IM, Kowdley, KV & Kwo, PY 2012, 'Anemia management in the era of triple combination therapy for chronic HCV', Gastroenterology and Hepatology, vol. 8, no. 9, pp. 3-15.
Jacobson, Ira M. ; Kowdley, Kris V. ; Kwo, Paul Y. / Anemia management in the era of triple combination therapy for chronic HCV. In: Gastroenterology and Hepatology. 2012 ; Vol. 8, No. 9. pp. 3-15.
@article{16556c92e6e64bd19e1c55d799abca30,
title = "Anemia management in the era of triple combination therapy for chronic HCV",
abstract = "Boceprevir or telaprevir plus ribavirin (RBV) and pegylated interferon-α (pegIFN-α) is the new standard-of-care therapy for patients who are chronically infected with genotype 1 hepatitis C virus (HCV). The addition of these protease inhibitors to the RBV/pegIFN-α combination regimen has significantly improved rates of sustained virologic response (SVR); however, the incidence of anemia has also increased significantly. Anemia can interfere with patients' quality of life, work productivity, and treatment adherence. Severe anemia can cause morbidity and even mortality. For the management of anemia during triple combination therapy, RBV dose reduction is recommended as an initial course of action. Retrospective analyses of carefully selected patient cohorts suggest that RBV dose reduction does not reduce SVR rates. However, this observation needs to be confirmed in prospective trials with cohorts that more accurately reflect the challenging patients treated in real-world practice. Adequate doses of RBV should be maintained during triple combination therapy, as phase II trials have demonstrated that RBV is essential for attaining optimal SVR rates and preventing viral breakthrough, relapse, and emergence of resistant variants. This roundtable addresses key points related to the management of anemia in the era of triple combination therapy, including the increasing problem of anemia, strategies for anemia management, and the importance of maintaining adequate RBV exposure as part of the HCV treatment regimen.",
author = "Jacobson, {Ira M.} and Kowdley, {Kris V.} and Kwo, {Paul Y.}",
year = "2012",
month = "9",
language = "English",
volume = "8",
pages = "3--15",
journal = "Gastroenterology and Hepatology",
issn = "1554-7914",
publisher = "Gastro-Hep Communications, Inc.",
number = "9",

}

TY - JOUR

T1 - Anemia management in the era of triple combination therapy for chronic HCV

AU - Jacobson, Ira M.

AU - Kowdley, Kris V.

AU - Kwo, Paul Y.

PY - 2012/9

Y1 - 2012/9

N2 - Boceprevir or telaprevir plus ribavirin (RBV) and pegylated interferon-α (pegIFN-α) is the new standard-of-care therapy for patients who are chronically infected with genotype 1 hepatitis C virus (HCV). The addition of these protease inhibitors to the RBV/pegIFN-α combination regimen has significantly improved rates of sustained virologic response (SVR); however, the incidence of anemia has also increased significantly. Anemia can interfere with patients' quality of life, work productivity, and treatment adherence. Severe anemia can cause morbidity and even mortality. For the management of anemia during triple combination therapy, RBV dose reduction is recommended as an initial course of action. Retrospective analyses of carefully selected patient cohorts suggest that RBV dose reduction does not reduce SVR rates. However, this observation needs to be confirmed in prospective trials with cohorts that more accurately reflect the challenging patients treated in real-world practice. Adequate doses of RBV should be maintained during triple combination therapy, as phase II trials have demonstrated that RBV is essential for attaining optimal SVR rates and preventing viral breakthrough, relapse, and emergence of resistant variants. This roundtable addresses key points related to the management of anemia in the era of triple combination therapy, including the increasing problem of anemia, strategies for anemia management, and the importance of maintaining adequate RBV exposure as part of the HCV treatment regimen.

AB - Boceprevir or telaprevir plus ribavirin (RBV) and pegylated interferon-α (pegIFN-α) is the new standard-of-care therapy for patients who are chronically infected with genotype 1 hepatitis C virus (HCV). The addition of these protease inhibitors to the RBV/pegIFN-α combination regimen has significantly improved rates of sustained virologic response (SVR); however, the incidence of anemia has also increased significantly. Anemia can interfere with patients' quality of life, work productivity, and treatment adherence. Severe anemia can cause morbidity and even mortality. For the management of anemia during triple combination therapy, RBV dose reduction is recommended as an initial course of action. Retrospective analyses of carefully selected patient cohorts suggest that RBV dose reduction does not reduce SVR rates. However, this observation needs to be confirmed in prospective trials with cohorts that more accurately reflect the challenging patients treated in real-world practice. Adequate doses of RBV should be maintained during triple combination therapy, as phase II trials have demonstrated that RBV is essential for attaining optimal SVR rates and preventing viral breakthrough, relapse, and emergence of resistant variants. This roundtable addresses key points related to the management of anemia in the era of triple combination therapy, including the increasing problem of anemia, strategies for anemia management, and the importance of maintaining adequate RBV exposure as part of the HCV treatment regimen.

UR - http://www.scopus.com/inward/record.url?scp=84868022874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868022874&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 3

EP - 15

JO - Gastroenterology and Hepatology

JF - Gastroenterology and Hepatology

SN - 1554-7914

IS - 9

ER -